20876-99-7

Basic information

• Product Name: 4-hydroxy-N,N-dimethylbenzamide
• Synonyms: Benzamide, 4-hydroxy-N,N-dimethyl-;Benzoic acid,4-hydroxy,amide,N,N-dimethyl;Inchi=1/C9H11no2/C1-10(2)9(12)7-3-5-8(11)6-4-7/H3-6,11H,1-2h;4-hydroxy-N,N-dimethylbenzamide(SALTDATA: FREE);4-hydroxy-N,N-dimethylbenzamide;AKOS BBS-00008691;OTAVA-BB 0117380127
• CAS NO: 20876-99-7
• Molecular Formula: C₉H₁₁NO₂
• Molecular Weight: 165.19
• Mol File: 20876-99-7.mol

Chemical Properties

• Melting Point: 161-162 °C(Solv: ethanol (64-17-5); water (7732-18-5))
• Boiling Point: 342.6°C at 760 mmHg
• Flash Point: 161°C
• Appearance: /
• Density: 1.153g/cm³
• Vapor Pressure: 3.74E-05mmHg at 25°C
• Refractive Index: 1.563
• PKA: 8.41±0.13(Predicted)
• CAS DataBase Reference: 4-hydroxy-N,N-dimethylbenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-hydroxy-N,N-dimethylbenzamide(20876-99-7)
• EPA Substance Registry System: 4-hydroxy-N,N-dimethylbenzamide(20876-99-7)

Safety Data

• Hazardous Substances Data: 20876-99-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-hydroxy-N,N-dimethylbenzamide is utilized as an analgesic and anti-inflammatory agent due to its ability to inhibit prostaglandin synthesis, which is linked to pain and inflammation.
Used in Neurodegenerative Disease Treatment:
4-hydroxy-N,N-dimethylbenzamide is employed as a potential therapeutic agent for neurodegenerative diseases, capitalizing on its antioxidative and neuroprotective effects to mitigate neuronal damage and disease progression.

InChI:InChI=1/C9H11NO2/c1-10(2)9(12)7-3-5-8(11)6-4-7/h3-6,11H,1-2H3

Upstream product

• 68-12-2 N,N-dimethyl-formamide 
• 99-96-7 4-hydroxy-benzoic acid 
• 106-41-2 4-bromo-phenol 
• 540-38-5 p-Iodophenol 
• 123-08-0 4-hydroxy-benzaldehyde 
• 7291-00-1 N,N-dimethyl-4-methoxybenzamide 
• 91640-47-0 4-allyloxy-N,N-dimethylbenzamide 
• 84403-55-4 4-(benzyloxy)-N,N-dimethylbenzamide 
• 27914-73-4 4-acetoxybenzoyl chloride 
• 20877-09-2 4-(dimethylcarbamoyl)phenyl acetate 
• 2345-34-8 4-acetyloxy-benzoic acid 

Downstream Products

• 41989-58-6 Isopropoxymethyl-phosphonothioic acid O-(4-dimethylcarbamoyl-phenyl) ester O-ethyl ester 
• 117022-51-2 4-(3-Chloro-propoxy)-N,N-dimethyl-benzamide 
• 1190090-01-7 C₂₄H₂₉N₃O₄ 
• 1245216-54-9 ethyl 4-(4-(dimethylcarbamoyl)phenoxy)-2-methyl-2H-indazole-6-carboxylate 
• 1158976-08-9 C₁₃H₁₇FN₂O₂*ClH 
• 1391926-57-0 C₁₆H₁₈ClN₅O₃ 
• 1345732-61-7 N,N-dimethyl-4-[(triisopropylsilyl)oxy]benzamide 
• 84403-55-4 4-(benzyloxy)-N,N-dimethylbenzamide 
• 91640-47-0 4-allyloxy-N,N-dimethylbenzamide 

Relevant articles and documents

A mild and practical method for deprotection of aryl methyl/benzyl/allyl ethers with HPPh2andtBuOK

A general method for the demethylation, debenzylation, and deallylation of aryl ethers using HPPh2andtBuOK is reported. The reaction features mild and metal-free reaction conditions, broad substrate scope, good functional group compatibility, and high chemical selectivity towards aryl ethers over aliphatic structures. Notably, this approach is competent to selectively deprotect the allyl or benzyl group, making it a general and practical method in organic synthesis.

POCl3 promoted metal-free synthesis of tertiary amides by coupling of carboxylic acids and N,N-disubstituted formamides

Herein we report a robust and synthetically useful catalyst-free amination methodology by the coupling of carboxylic acids and N-substituted formamides using POCl3 as a promoter. Versatile amides with a wide array of substituent groups were prepared within only 1 h in good to excellent yields. And even multi-substituted aromatic carboxylic acids could give the desired products with satisfactory results.

Synthesis method of amide aryl compound

The invention relates to a synthesis method of an amide aryl compounds. According to the method, Ru-(p-cymene) C12 is taken as a catalyst, K2S2O8 is taken as an oxidizing agent, Xantphos is taken as a ligand, one reactant (N, N-dialkyl formamide) is taken

Facile Access to Amides from Oxygenated or Unsaturated Organic Compounds by Metal Oxide Nanocatalysts Derived from Single-Source Molecular Precursors

Oxidative amidation is a valuable process for the transformation of oxygenated organic compounds to valuable amides. However, the reaction is severely limited by the use of an expensive catalyst and limited substrate scope. To circumvent these limitations, designing a transition-metal-based nanocatalyst via more straightforward and economical methodology with superior catalytic performances with broad substrate scope is desirable. To resolve the aforementioned issues, we report a facile method for the synthesis of nanocatalysts NiO and CuO by the sol-gel-assisted thermal decomposition of complexes [Ni(hep-H)(H2O)4]SO4 (SSMP-1) and [Cu(μ-hep)(BA)]2 (SSMP-2) [hep-H = 2-(2-hydroxylethyl)pyridine; BA = benzoic acid] as single-source molecular precursors (SSMPs) for the oxidative amidation of benzyl alcohol, benzaldehyde, and BA by using N,N-dimethylformamide (DMF) as the solvent and as an amine source, in the presence of tert-butylhydroperoxide (TBHP) as the oxidant, at T = 80 °C. In addition to nanocatalysts NiO and CuO, our previously reported Co/CoO nanocatalyst (CoNC), derived from the complex [CoII(hep-H)(H2O)4]SO4 (A) as an SSMP, was also explored for the aforementioned reaction. Also, we have carefully investigated the difference in the catalytic performance of Co-, Ni-, and Cu-based nanoparticles synthesized from the SSMP for the conversion of various oxygenated and unsaturated organic compounds to their respective amides. Among all, CuO showed an optimum catalytic performance for the oxidative amidation of various oxygenated and unsaturated organic compounds with a broad reaction scope. Finally, CuO can be recovered unaltered and reused for several (six times) recycles without any loss in catalytic activity.

Ru-catalyzed direct amidation of carboxylic acids with N-substituted formamides

The direct amidation of carboxylic acids with N-substituted formamides has been accomplished via ruthenium catalysis. In the presence of ruthenium catalyst, a versatile range of carboxylic acids and N-substituted formamides undergoes amidation reaction to produce synthetically useful amides in good yields. C[dbnd]O in amide product came from benzoic acid but not N-substituted formamides, and which was confirmed by Isotope experiment.

Method for synthesizing phosphorus-oxychloride-promoted amide compound

The invention relates to a method for synthesizing a phosphorus-oxychloride-promoted amide compound. The synthesizing method includes the steps that carboxylic acid serves as one reactant, another reactant (N,N-dialkyl methanamide) serves as a solvent, one equivalent of phosphorus oxychloride is added, and the amide compound is prepared. The reaction substrates are low in price and easy to get, the nature is stable, toxicity is small, the reaction speed is high, conditions are moderate, and the reaction substrates can be widely applied to substrates with different functional groups. The efficiently-constructed amide compound is an important molecular skeleton for many medicines, bioactive molecules and natural products, and the synthesizing method is a widely-applicable preparing method for synthesizing the compound.

Discovery of Novel and Orally Bioavailable Inhibitors of PI3 Kinase Based on Indazole Substituted Morpholino-Triazines

A new class of potent PI3Kα inhibitors is identified based on aryl substituted morpholino-triazine scaffold. The identified compounds showed not only a high level of enzymatic and cellular potency in nanomolar range but also high oral bioavailability. The three lead molecules (based on their in vitro potency) when evaluated further for in vitro metabolic stability as well as pharmacokinetic profile led to the identification of 26, as a candidate for further development. The IC50 and EC50 value of 26 is 60 and 500 nM, respectively, for PI3Kα enzyme inhibitory activity and ovarian cancer (A2780) cell line. The identified lead also showed a high level of microsomal stability and minimal inhibition activity for CYP3A4, CYP2C19, and CYP2D6 at 10 μM concentrations. The lead compound 26, demonstrated excellent oral bioavailability with an AUC of 5.2 μM at a dose of 3 mpk in mice and found to be well tolerated in mice when dosed at 30 mpk BID for 5 days.

NOVEL TRIAZINE COMPOUNDS

The present invention relates to novel triazine compounds of formula (1). The present invention also discloses compounds of formula I along with other pharmaceutical ac-ceptable excipients and use of the compounds to modulate the PI3K/ mTOR pathway

Silicadiphenyl phosphinite (SDPP)/Pd(0) nanocatalyst for efficient aminocarbonylation of aryl halides with POCl3 and DMF

Silicadiphenyl phosphinite (SDPP) as a new phosphorylated silica and catalytic amounts of Pd(II) generates nano SDPP/Pd(0) catalyst for the efficient aminocarbonylation of aryl halides in the presence of POCl3 and N,N-dimethylformamide (DMF). Amides are obtained in high yields from aryl iodides and also activated aryl bromides, chlorides.

NOVEL TRIAZINE COMPOUNDS

The present invention relates to novel triazine compounds of formula (1), methods of their preparation, pharmaceutical compositions containing these compounds and the use of these compounds to treat proliferative disorders such as tumors and cancers and also other conditions and disorders related to or associated with dysregulation of PI3 Kinases, PI3 Kinase pathway, mTOR and/ or the mTOR pathway.